New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
07:24 EDTADXS, VRTX, RNA, RARE, PLX, NPSP, NLNK, ISIS, GEVA, FOLD, CYTK, CNAT, XOMACanaccord to hold a conference
Orphan Drugs 1:1 Day will be held in New York on February 24.
Check below for free stories on ADXS;CNAT;CYTK;FOLD;GEVA;ISIS;NLNK;NPSP;PLX;RARE;RNA;VRTX;XOMA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 20, 2014
06:34 EDTFOLDAmicus Therapeutics to host conference call
Conference call to discuss results of Phase 3 Fabry monotherapy study will be held on August 20 at 8 am. Webcast Link
06:08 EDTFOLDAmicus Therapeutics reports positive Phase 3 data from Fabry study
Subscribe for More Information
August 18, 2014
11:41 EDTNPSPCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 15, 2014
10:01 EDTNPSPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:12 EDTNPSPNPS Pharmaceuticals initiated with an Outperform at FBR Capital
Target $34.
07:01 EDTISISIsis Pharmaceuticals earns $2M from advancement of ISIS-SMN from Biogen
Isis Pharmaceuticals (ISIS) announced that it has earned a $2M milestone payment from Biogen (BIIB) related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy.
August 14, 2014
16:21 EDTCNATConatus files $150M mixed securities shelf
Subscribe for More Information
10:53 EDTCNATHigh option volume stocks
Subscribe for More Information
August 13, 2014
18:55 EDTCNATOn The Fly: After Hours Movers
UP AFTER EARNINGS: Aspen Technology (AZPN), up almost 3% after reporting better than expected Q4 results and giving Q1 and FY15 guidance on its earnings conference call. ALSO HIGHER: Kindred Healthcare (KND), up more than 1% after Point72 reported a 5.1% passive stake in the company. DOWN AFTER EARNINGS: Cisco Systems (CSCO), down 1.2% after reporting Q4 results, giving Q1 guidance, and announcing that it is cutting 8% of its workforce... Noodles & Company (NDLS), down 21.2% after reporting Q2 results and "tempering" its FY14 outlook... Conatus Pharmaceuticals (CNAT), down 13.6% after reporting Q2 results and announcing it is deferring the results of its NAFLD/NASH clinical trial to 1Q15. ALSO LOWER: Amgen (AMGN), down 2.15% after announcing the Phase 3 Kyprolis FOCUS clinical trial did not meet its primary endpoint.
16:57 EDTCNATConatus Phase 2 NAFLD/NASH clinical trial results announcement deferred to 1Q15
Subscribe for More Information
16:05 EDTCNATConatus reports Q2 EPS (34c), consensus (40c)
Subscribe for More Information
14:45 EDTVRTXVertex volatility at record low
Subscribe for More Information
13:27 EDTNLNKNewLink could start testing Ebola vaccine soon, Reuters reports
Subscribe for More Information
13:20 EDTNLNKNewLink Genetics CEO says safety trial of Ebola vaccine could start 'in weeks'
Subscribe for More Information
August 12, 2014
12:24 EDTRNAProsensa accelerated or conditional approvals likely, says Roth Capital
Subscribe for More Information
10:15 EDTCNATIntercept surges after reporting data for liver disease drug OCA
Subscribe for More Information
09:21 EDTCNATOn The Fly: Pre-market Movers
Subscribe for More Information
August 11, 2014
16:07 EDTRNAProsensa to get additional funding from nonprofit CureDuchenne
Prosensa Holding announced that an affiliate of CureDuchenne, a U.S. national nonprofit organization dedicated to finding a cure for Duchenne Muscular Dystrophy, or DMD, will provide Prosensa with up to EUR5M by means of convertible promissory notes to support the company and accelerate the development and patient access of much needed DMD therapies. The closing of EUR4.5M of the notes is contingent upon specified milestones in the advancement of drisapersen and the company's other exon skipping candidates in Prosensa's DMD portfolio. The funding arrangement will assist the company in progressing the second exon skipping candidate for the treatment of DMD, PRO044, by initiating a Phase II clinical extension study in Europe by the end of 2014 and a placebo-controlled trial in the U.S. in the first half of 2015, which may serve as one of two confirmatory studies to support a potential accelerated approval for drisapersen. It will also support re-dosing efforts for drisapersen clinical trial participants in North America and Europe and facilitate the drug's New Drug Application filing in the U.S. in 2014 along with the development of other Prosensa's other exon skipping compounds, PRO045 and PRO053.
15:27 EDTRNAWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
09:04 EDTRAREUltragenyx reports Q2 EPS (45c), consensus (42c)
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use